Ciphergen and Ohio State University Research Foundation Sign Collaborative Agreement to Develop Diagnostic Test for Blood Disord
28 Novembre 2006 - 3:00PM
PR Newswire (US)
FREMONT, Calif., Nov. 28 /PRNewswire-FirstCall/ -- Ciphergen
Biosystems, Inc. (NASDAQ:CIPH) and Ohio State University Research
Foundation (OSURF) today announced a collaborative agreement to
develop and clinically validate a diagnostic test to detect
thrombotic thrombocytopenic purpura (TTP), a hematologic disease.
"A clinical diagnostic test that can rapidly detect deficiencies in
the enzyme activity associated with TTP will help physicians more
effectively manage this devastating disease," said Haifeng M. Wu,
M.D., Assistant Professor of Pathology and Medicine and Director of
Clinical Coagulation Laboratory at Ohio State University Medical
Center. "This test will help physicians determine when to initiate
plasma exchange and monitor response to this therapy." Annual
testing opportunities exist to 1) diagnose patients with TTP; 2)
evaluate patient responses to therapy; and 3) monitor patients
during clinical remission to prevent recurrences of the disease.
"Working together with Dr. Wu and Ohio State University Research
Foundation, we will optimize a SELDI-based test, which has the
advantage of reproducibly and accurately measuring the product of
the enzymatic reaction that underlies this disease," said Eric T.
Fung, M.D., Ph.D., Chief Scientific Officer for Ciphergen
Biosystems. "Current testing methods to diagnose TTP lack this
quantitation and ease of use." Under the terms of the agreement,
OSURF and Ciphergen will optimize the assay to measure enzyme and
antibody inhibition activity, and will jointly conduct multi-center
studies to validate the test. Financial terms of the agreement were
not disclosed. About Thrombotic Thrombocytopenic Purpura (TTP) TTP
is a blood disorder characterized by low platelets, low red blood
cell count (caused by premature breakdown of the cells),
neurological abnormalities and sometimes abnormalities in kidney
function. In most cases, this disease is caused by a deficiency in
or auto-antibodies to an enzyme called ADAMTS13, which cleaves von
Willebrand Factor. Loss of this enzyme causes platelet clumping and
red blood cell destruction that are the hallmarks of TTP. About
Ciphergen Ciphergen Biosystems, Inc. is dedicated to the discovery,
development and commercialization of novel high-value diagnostic
tests that help physicians diagnose, treat and improve outcomes for
patients. Ciphergen, along with its prestigious scientific
collaborators, has ongoing diagnostic programs in
oncology/hematology, cardiology and women's health with an initial
focus in ovarian cancer. Based in Fremont, California, more
information about Ciphergen can be found on the Web at
http://www.ciphergen.com/ . Safe Harbor Statement Note Regarding
Forward-Looking Statements: This press release contains
forward-looking statements. For purposes of the Private Securities
Litigation Reform Act of 1995 (the "Act"), Ciphergen disclaims any
intent or obligation to update these forward-looking statements,
and claims the protection of the Safe Harbor for forward-looking
statements contained in the Act. Examples of such forward-looking
statements include statements regarding the development and
performance of a clinical diagnostic test for TTP and the
advantages of such a test compared to current testing methods.
Actual results may differ materially from those projected in such
forward-looking statements due to various factors, including the
possibility that Ciphergen and its partner may not be able to
conduct studies which validate the clinical diagnostic test for TTP
or otherwise successfully develop such a test. Investors should
consult Ciphergen's filings with the Securities and Exchange
Commission, including its Form 10-Q filed November 20, 2006, for
further information regarding these and other risks related to the
Company's business. DATASOURCE: Ciphergen Biosystems, Inc. CONTACT:
Sue Carruthers, Investor Relations, Ciphergen Biosystems, Inc.,
+1-510-505-2233; or media, Daryl Messinger of WeissComm Partners,
+1-415-946-1062, for Ciphergen Biosystems, Inc. Web site:
http://www.ciphergen.com/
Copyright
Grafico Azioni Ciphergen Biosystems (NASDAQ:CIPH)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Ciphergen Biosystems (NASDAQ:CIPH)
Storico
Da Mag 2023 a Mag 2024
Notizie in Tempo Reale relative a Ciphergen Biosystems (MM) (NASDAQ): 0 articoli recenti
Più Ciphergen Biosystems (MM) Articoli Notizie